Chymotrypsins are pancreatic enzymes, released into pancreatic duct, responsible for break down of proteins in the gut. A reduced concentration of faecal chymotrypsins has been used as a marker for pancreatic exocrine insufficiency.
Faecal chymotrypsin (FCT) versus faecal pancreatic elastase (FPE) test :
- FCT activity is reduced in more acidic faeces. Optimum pH is 8.5-9.5. FPE is stable in acidic pH.
- Method of testing is different: In FCT, chymotrypsin enzyme activity is measured. In FPE, elastase quantity is measured
- Both FCT and FPE are not sensitive for mild pancreatic exocrine insufficiency. FCT detects around 25% of mild disease.
- FCT detects around 86% of severe pancreatic disease, 50% of moderate pancreatic disease. Majority (not all) studies suggest FPE has slightly better sensitivity for moderate to severe pancreatic insufficiency than FCT.
- FPE test carries a higher cost
- FPE is not capable of assessing pancreatic supplement response - chymotrypsin is contained in pancreatic supplements but not elastase. However, if the intrinsic pancreatic function is to be assessed, prior withholding of pancreatic supplement is not required for FPE test.
False positives (non-structural pancreatic diseases) :
- Watery diarrhoea
- In intestinal mucosal atrophic diseases e.g coeliac disease or in protein malnutrition state - functional pancreatic insufficiency secondary to reduced enterohormones
- Uraemic pancreatopathy - no gross anatomical features but histological features similating chronic pancreatitis
False negatives :
- Mild pancreatic insufficiency
- Post antibiotic therapy, presumably by reducing bacterial degradation or inhibition on the enzyme (ref: Remtulla MA Clin Biochem 1986; 19:341-347)
- Post ileal resection and radiation ileitis (especially distal ileal disease) - presumably reflect removal of an inhibitory mechanism on pancreatic secretion
Faecal chymotrypsin and daily faecal fat excretion
FCT bears no direct relationship with faecal fat excretion and cannot distinguish healthy subjects from patients with pancreatic and/or non-pancreatic steatorrhoea
References:
Moss DW, Henderson AR. Clinical enzymology (chapter 22) in Tietz textbook of Clinical Chemistry (3rd edition, 1999) Burtis CA, Ashwood ER (eds) W.B. Saunders company, Philadelphia, Pennsylvania
Chowdury RS et al Aliment Pharmacol Ther 2003; 17:733-750
Remtulla MA et al Clin Biochem 1986; 19:341-347
Carroccio A et al Gut 1991; 32:796-9
Ventrucci M et al Dig Dis Sci 2000; 45(11): 2265-69
Stockbrugger RW et al Scan J Gastroenterol suppl 1991; 188:13-9
Also see Pancreatic Elastase
Emails to
chemicalpathologist@adhb.govt.nz
will receive priority attention from the on-call chemical pathologist.
If the query concerns a specific patient please include the NHI number in your email.
If email is not a suitable option, please contact the on-call chemical pathologist via
Lablink (Auckland City Hospital ext. 22000 or 09-3078995).
Individual chemical pathologists may be contacted but will not be available at all times.
After-hours
: contact
Lablink (Auckland City Hospital ext. 22000 or 09-3078995) or hospital operator for on duty staff after hours.
Dr Samarina Musaad
(Clinical Lead)
:
SamarinaM@adhb.govt.nz
ext. 22402
Dr Cam Kyle:
CampbellK@adhb.govt.nz
ext 22052
Dr Weldon Chiu:
WeldonC@adhb.govt.nz
ext. 23427
Dr Campbell Heron:
CHeron@adhb.govt.nz
ext. 23427
Dr Sakunthala Jayasinghe:
Sakunthala@adhb.govt.nz
ext. 23427